NeOnc Technologies Partners with CBCC Global Research to Accelerate Brain Cancer Clinical Trials in India
• NeOnc Technologies has formed a strategic partnership with CBCC Global Research to expand its clinical trial network to 30 FDA-compliant research sites across India, focusing on neuro-oncology treatments.
• The collaboration will initially focus on the NEO100-01 Phase 2a trial for Glioblastoma (GBM), evaluating an intranasal ultra-purified perillyl alcohol therapy targeting IDH1 mutations in Grade 3 and 4 tumors.
• NeOnc aims to complete Phase 2 enrollment this year with results expected 6-8 months later, potentially accelerating the development timeline for novel brain cancer therapies while reaching a more diverse patient population.
© Copyright 2025. All Rights Reserved by MedPath